liraglutide sold brand names victoza saxenda among others antidiabetic medication used treat type diabetes chronic secondline therapy diabetes following firstline therapy effects longterm health outcomes like heart disease life expectancy given injection liraglutide glucagonlike receptor agonist receptor agonist also known incretin works increasing insulin release pancreas decreases excessive glucagon common side effects include low blood sugar nausea dizziness abdominal pain pain site gastrointestinal sideeffects tend strongest beginning treatment period subside serious side effects may include angioedema pancreatitis gallbladder disease kidney use pregnancy breastfeeding unclear black box warning cautions medullary thyroid cancers observed rats treated liraglutide unknown whether liraglutide causes thyroid ccell tumors including medullary thyroid carcinoma mtc humans relevance humans tumors rodents liraglutide approved medical use european union united states commonly prescribed medication united states million liraglutide medication used treatment type diabetes liraglutide improves control blood patients high cardiovascular risk liraglutide shown reduce risk first occurrence death cardiovascular causes nonfatal myocardial infarction nonfatal ada guidelines currently consider liraglutide first line pharmacologic therapy type diabetes usually together metformin specifically patients atherosclerotic cardiovascular disease cochrane review showed reduction liraglutide mg compared insulin glargine exenatide Âµg twice daily sitagliptin rct comparing liraglutide glargine glimepiride sitagliptin added metformin followup years glargine liraglutide modestly effective achieving maintaining target difference outcomes microvascular cardiovascular liraglutide may also used together diet exercise chronic weight management liraglutide led greater weight loss previous glucagonlike peptide less effective standard weight loss dose exposures eight times greater used humans liraglutide caused statistically significant increase thyroid tumors rats clinical relevance findings clinical trials rate thyroid tumors patients treated liraglutide per patient years people compared per patients person comparison groups sole person comparator group four five persons liraglutide group serum markers elevated calcitonin suggestive preexisting disease fda said serum calcitonin biomarker medullary thyroid cancer slightly increased liraglutide patients still within normal ranges required ongoing monitoring years cancer group johns hopkins reported apparently statistically significant association hospitalization acute pancreatitis prior treatment derivatives exenatide inhibitors response united states fda european medicines agency conducted review available data regarding possible connection incretin mimetics pancreatitis pancreatic cancer joint letter new england journal medicine agencies concluded pooled analysis data patients type diabetes clinical trials sitagliptin database provided compelling evidence increased risk pancreatitis pancreatic cancer agencies agree assertions concerning causal association incretinbased drugs pancreatitis pancreatic cancer expressed recently scientific literature media inconsistent current data fda ema reached final conclusion time regarding causal relationship although totality data reviewed provides reassurance pancreatitis continue considered risk associated drugs data available agencies continue investigate safety liraglutide acylated glucagonlike agonist derived human less common form endogenous reduces mealrelated hyperglycemia hours administration increasing insulin secretion required increasing glucose levels delaying gastric emptying suppressing prandial glucagon liraglutide leads insulin release pancreatic beta cells presence elevated blood glucose insulin secretion subsides glucose concentrations decrease approach euglycemia normal blood glucose level also decreases glucagon secretion glucosedependent manner delays gastric emptying unlike endogenous liraglutide stable metabolic degradation peptidases plasma halflife endogenous plasma halflife minutes due degradation ubiquitous enzymes dipeptidyl neutral endopeptidases nep halflife intramuscular injection approximately half hour even administered way limited use therapeutic agent metabolically active forms endogenous rare prolonged action liraglutide achieved attaching fatty acid molecule one position molecule enabling selfassociate bind albumin within subcutaneous tissue bloodstream active released albumin slow consistent rate albumin binding also results slower degradation reduced renal elimination compared liraglutide marketed brand name victoza us uk uae kuwait india iran canada europe japan philippines launched germany italy denmark netherlands sweden japan canada united states france indonesia malaysia singapore liraglutide also known marketed saxenda norway australia germany indonesia iran israel canada brazil switzerland united kingdom ireland south korea us also enligria quinliro liraglutide approved us food drug administration fda european medicines agency ema adults body mass index bmi greater obesity bmi greater overweight least one weightrelated liraglutide approved fda treatment children years older type diabetes making first noninsulin drug approved treat type diabetes children since metformin approved novo nordisk stated plans use sales force united states promote saxenda considered potential sales billion year within years launch around world analysts citi research concur assuming drug reach less percent million people united states classified obese daily price months use company estimates spent billion ten years take saxenda research novo nordisk made deals generic manufacturers enter united states market novo nordisk breached abpis code conduct failing provide information side effects promoting prior granted market nonprofit consumer advocacy group public citizen petitioned us food drug administration fda immediately remove liraglutide market concluded risks thyroid cancer pancreatitis outweigh documented novo nordisk agreed pay million settle multiple whistleblower lawsuits alleging company illegally marketed promoted sold victoza offlabel uses type diabetes violation federal food drug cosmetic act false claims novo nordisk paid additional million states california illinois settle whistleblower cases alleging fraud private commercial health httpsenwikipediaorgwikiliraglutide